Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Posted by Geri Gentry on Aug 28th, 2026

Shares of Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.04 and traded as high as $4.21. Galectin Therapeutics shares last traded at $4.15, with a volume of 291,096 shares trading hands.

Wall Street Analysts Forecast Growth

GALT has been the subject of several recent analyst reports. Weiss Ratings raised shares of Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. Wall Street Zen upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Zacks Research raised shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, June 23rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $11.00.

Get Our Latest Stock Analysis on GALT

Galectin Therapeutics Stock Down 2.2%

The firm’s fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.05. The stock has a market capitalization of $266.72 million, a PE ratio of -9.42 and a beta of 0.41.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.05). As a group, analysts predict that Galectin Therapeutics Inc. will post -0.3 EPS for the current year.

Insider Buying and Selling at Galectin Therapeutics

In related news, insider Khurram Jamil sold 47,467 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $5.04, for a total transaction of $239,233.68. Following the completion of the sale, the insider owned 2,037 shares in the company, valued at approximately $10,266.48. This represents a 95.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Harold H. Shlevin sold 22,268 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.04, for a total value of $112,230.72. Following the sale, the director owned 6,500 shares of the company’s stock, valued at approximately $32,760. This trade represents a 77.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 89,594 shares of company stock worth $436,703 over the last three months. Insiders own 52.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Hopwood Nicholas Hunter bought a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at about $322,000. Archer Investment Corp bought a new position in shares of Galectin Therapeutics in the 2nd quarter worth approximately $81,000. Argyle Capital Partners LLC purchased a new position in shares of Galectin Therapeutics in the second quarter worth approximately $62,000. Bank of New York Mellon Corp purchased a new position in shares of Galectin Therapeutics in the second quarter worth approximately $491,000. Finally, Bank of America Corp DE grew its position in Galectin Therapeutics by 114.9% during the first quarter. Bank of America Corp DE now owns 53,862 shares of the company’s stock valued at $150,000 after buying an additional 28,799 shares during the period. 11.68% of the stock is owned by hedge funds and other institutional investors.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.